Newborn screening for Pompe disease: Parental experiences and follow-up care for a late-onset diagnosis

J Genet Couns. 2022 Dec;31(6):1404-1420. doi: 10.1002/jgc4.1615. Epub 2022 Aug 1.

Abstract

Newborn screening (NBS) for Pompe disease (PD) was added to the Recommended Uniform Screening Panel (RUSP) in the United States in 2015 because there was compelling evidence of health benefits for early diagnosis of Infantile-onset Pompe disease (IOPD). However, one limitation of NBS for PD is its inability to distinguish IOPD and late onset forms of Pompe disease (LOPD). Management of LOPD is challenging because of uncertainty around progression of LOPD and determining the appropriate time for treatment initiation. The aims of this study were to understand the impact of LOPD identified through NBS, by exploring the differences in attitudes, emotions and opinions among parents and identify their needs for follow-up care. Study participants were recruited from states that included PD on their NBS panel. Semi-structured interviews were conducted with parents of nine children who were diagnosed with LOPD after an abnormal NBS result. Predominantly, parents reported a lack of adequate information, guidance, and psychosocial support from the very beginning and through the course of their diagnosis. This caused uncertainty, anxiety, frustration, and fear of the unknown. Parents live in a 'worry or not to worry' phase, balancing between coping methods to avoid over medicalization of their child, but also preparing concrete follow-up plans to be on the lookout for any signs of PD-related symptoms. Understanding parents' experiences allows genetic counselors and NBS programs to proactively design care plan for parents during this difficult period.

Keywords: Pompe disease; genetic counselors; long-term follow-up; newborn screening; parental experiences; public health.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aftercare
  • Child
  • Delayed Diagnosis
  • Glycogen Storage Disease Type II* / diagnosis
  • Glycogen Storage Disease Type II* / genetics
  • Glycogen Storage Disease Type II* / therapy
  • Humans
  • Infant, Newborn
  • Neonatal Screening / methods
  • Parents / psychology